Retraction notice to “MiR-1290 promotes cancer progression by targeting nuclear factor I/X(NFIX) in esophageal squamous cell carcinoma (ESCC)” [Biomed. Pharmacother. 76 (2015) 82–93, (S0753332215300688), (10.1016/j.biopha.2015.10.005)];MiR-1290 promotes cancer progression by targeting nuclear factor I/X(NFIX) in esophageal squamous cell carcinoma (ESCC)

Biomedicine and Pharmacotherapy

Volumn 76, Issue , 2015, Pages 82-93

  Mao, Yu ^a,b   Liu, Jia ^b,c   Zhang, Dakai ^b,c   Li, Baosheng ^b  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

ESCC; MiR 1290; NFIX; Progression

Indexed keywords

MICRORNA; MICRORNA 1290; NUCLEAR FACTOR; NUCLEAR FACTOR I; NUCLEAR FACTOR X; UNCLASSIFIED DRUG; MESSENGER RNA; MIRN1290 MICRORNA, HUMAN; NFIX PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; ARTICLE; BINDING SITE; BIOINFORMATICS; CANCER GROWTH; CANCER STAGING; CELL CYCLE PHASE; CELL CYCLE REGULATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FLUORESCENCE MICROSCOPY; GENE CONTROL; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; PREDICTION; PRIORITY JOURNAL; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CELL MOTION; DISEASE COURSE; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR INVASION; VALIDATION STUDY;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; NFI TRANSCRIPTION FACTORS; RNA, MESSENGER;

EID: 84949220651     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2024.116189     Document Type: Erratum

References (17)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127:2893-2917.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
3. Siewert J.R., Ott K. Are squamous and adenocarcinomas of the esophagus the same disease. Semin. Radiat. Oncol. 2007, 17:38-44.
4. Usui S., Minami Y., Shiozawa T., Iyama S., Satomi K., Sakashita S., et al. Differences in the prognostic implications of vascular invasion between lung adenocarcinoma and squamous cell carcinoma. Lung Cancer 2013, 82:407-412.
5. Nebl G., Cato A.C. NFI/X proteins: a class of NFI family of transcription factors with positive and negative regulatory domains. Cell. Mol. Biol. Res. 1995, 41:85-95.
6. Piper M., Harris L., Barry G., Heng Y.H., Plachez C., Gronostajski R.M., et al. Nuclear factor one x regulates the development of multiple cellular populations in the postnatal cerebellum. J. Comp. Neurol. 2011, 519:3532-3548.
7. Shin G., Kang T.W., Yang S., Baek S.J., Jeong Y.S., Kim S.Y. GENT gene expression database of normal and tumor tissues. Cancer Inf. 2011, 10:149-157.
8. Wu J., Ji X., Zhu L., Jiang Q., Wen Z., Xu S., et al. Up-regulation of microRNA-1290 impairs cytokinesis and affects the reprogramming of colon cancer cells. Cancer Lett. 2013, 329:155-163.
9. Dai N., Zhong Z.Y., Cun Y.P., Qing Y., Chen C., Jiang P., et al. Alteration of the microRNA expression profile in human osteosarcoma cells transfected with APE1 siRNA. Neoplasma 2013, 60:384-394.
10. Li M., He X.Y., Zhang Z.M., Li S., Ren L.H., Cao R.S., et al. MicroRNA-1290 promotes esophageal squamous cell carcinoma cell proliferation and metastasis. World J. Gastroenterol.: WJG 2015, 21:3245-3255.
11. -δδCT method. Methods 2001, 25:402-408.
12. Pennathur A., Gibson M.K., Jobe B.A., Luketich J.D. Oesophageal carcinoma. Lancet 2013, 381:400-412.
13. Endo Y., Yamashita H., Takahashi S., Sato S., Yoshimoto N., Asano T., et al. Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer. BMC Cancer 2014, 14:990.
14. Huang X., Yuan T., Liang M., Du M., Xia S., Dittmar R., et al. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur. Urol. 2015, 67:33-41.
15. Li A., Yu J., Kim H., Wolfgang C.L., Canto M.I., Hruban R.H., et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin. Cancer Res. 2013, 19:3600-3610.
16. Messina G., Biressi S., Monteverde S., Magli A., Cassano M., Perani L., et al. Nfix regulates fetal-specific transcription in developing skeletal muscle. Cell 2010, 140:554-566.
17. Heng Y.H., Zhou B., Harris L., Harvey T., Smith A., Horne E., et al. NFIX regulates proliferation and migration within the murine SVZ neurogenic niche. Cereb. Cortex 2014.